tetano
Editor, Senior Moderator
J Clin Microbiol
. 2022 Mar 7;e0048221.
doi: 10.1128/jcm.00482-21. Online ahead of print.
Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
Anisha Misra[SUP] 1 [/SUP], Elitza S Theel[SUP] 1 [/SUP]
Affiliations
Abstract
Preexisting immunity to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was nonexistent in humans, which coupled with high transmission rates of certain SARS-CoV-2 variants and limited vaccine uptake or availability, has collectively resulted in an ongoing global pandemic. The identification and establishment of one or multiple correlates of protection (CoP) against infectious pathogens is challenging, but beneficial from both the patient care and public health perspectives. Multiple studies have shown that neutralizing antibodies, whether generated following SARS-CoV-2 infection, vaccination, or a combination of both (i.e., hybrid immunity), as well as adaptive cellular immune responses, serve as CoPs for COVID-19. However, the diverse number and type of serologic assays, alongside the lack of cross-assay standardization and emergence of new SARS-CoV-2 variants with immune evasive characteristics, have collectively posed challenges to determining a robust CoP 'threshold' and for the routine utilization of these assays to document 'immunity,' as is commonly done for other vaccine preventable diseases. Here, we discuss what CoPs are, review our current understanding of infection-induced, vaccine-elicited and hybrid immunity to COVID-19 and summarize the current and potential future utility of SARS-CoV-2 serologic testing.
Keywords: COVID-19; SARS-CoV-2; antibodies; correlate of protection; serology; vaccines.
. 2022 Mar 7;e0048221.
doi: 10.1128/jcm.00482-21. Online ahead of print.
Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
Anisha Misra[SUP] 1 [/SUP], Elitza S Theel[SUP] 1 [/SUP]
Affiliations
- PMID: 35249377
- DOI: 10.1128/jcm.00482-21
Abstract
Preexisting immunity to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was nonexistent in humans, which coupled with high transmission rates of certain SARS-CoV-2 variants and limited vaccine uptake or availability, has collectively resulted in an ongoing global pandemic. The identification and establishment of one or multiple correlates of protection (CoP) against infectious pathogens is challenging, but beneficial from both the patient care and public health perspectives. Multiple studies have shown that neutralizing antibodies, whether generated following SARS-CoV-2 infection, vaccination, or a combination of both (i.e., hybrid immunity), as well as adaptive cellular immune responses, serve as CoPs for COVID-19. However, the diverse number and type of serologic assays, alongside the lack of cross-assay standardization and emergence of new SARS-CoV-2 variants with immune evasive characteristics, have collectively posed challenges to determining a robust CoP 'threshold' and for the routine utilization of these assays to document 'immunity,' as is commonly done for other vaccine preventable diseases. Here, we discuss what CoPs are, review our current understanding of infection-induced, vaccine-elicited and hybrid immunity to COVID-19 and summarize the current and potential future utility of SARS-CoV-2 serologic testing.
Keywords: COVID-19; SARS-CoV-2; antibodies; correlate of protection; serology; vaccines.